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Abstract
Venezuelan equine encephalitis (VEE) is a reemerging, mosquito-borne viral disease of the neotropics that is severely
debilitating and sometimes fatal to humans. Periodic epidemics mediated by equine amplification have been recognized
since the 1920s, but interepidemic disease is rarely recognized. We report here clinical findings and genetic characterization
of 42 cases of endemic VEE detected in Panama from 1961–2004. Recent clusters of cases occurred in Darien (eastern
Panama) and Panama provinces (central Panama) near rainforest and swamp habitats. Patients ranged from 10 months to
48 years of age, and the more severe cases with neurological complications, including one fatal infection, were observed in
children. The VEE virus strains isolated from these cases all belonged to an enzootic, subtype ID lineage known to circulate
among sylvatic vectors and rodent reservoir hosts in Panama and Peru. These findings underscore endemic VEE as an
important but usually neglected arboviral disease of Latin America.
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Introduction
Venezuelan equine encephalitis virus (VEEV) is the most
important alphaviral (Togaviridae: Alphavirus) pathogen of humans
and domestic animals in the western hemisphere [1,2]. Most
human and animal disease occurs when VEEV undergoes an
amplification cycle where equids (horses, donkeys and mules)
become infected and develop high titer viremia, facilitating
transmission by Aedes and Psorophora spp. mosquitoes to susceptible
equids or people. The VEEV strains involved in this equid
amplification cycle belong to subtypes IAB and IC, and are called
epizootic or epidemic (henceforth called epidemic). These strains
arise periodically and repeatedly via mutation of enzootic VEEV
subtypes [3]. The resulting epidemics typically involve tens-to-
hundreds of thousands of cases in humans and equids. Human
disease is highly debilitating and immunosuppressive, and
occasionally fatal (less than 1% of cases); however, many persons,
especially children, suffer permanent neurological sequelae [2,4].
In equids, VEEV causes mortality in roughly half of infected
animals, resulting in major effects on agricultural activities that
rely on these animals in many parts of Latin America.
The progenitors of the epidemic VEEV strains are called
enzootic viruses, are not associated with equine disease, and
circulate more or less continuously in forested or swamp habitats
where rodents serve as the reservoir hosts and mosquitoes in the
subgenus Culex (Melanoconion) act as vectors [5]. These enzootic
strains were first isolated in the 1950’s, and a fatal human isolate
made in Panama in 1961 [6] was later identified as a subtype ID
enzootic strain. The enzootic VEEV cycle, which involves
subtypes ID and IE, often goes undetected because these viruses
are incapable of exploiting these hosts for amplification to produce
widespread disease [2,4]. However, enzootic VEEV strains are
increasingly recognized as important endemic pathogens of people
who live near the enzootic transmission foci and/or enter the
habitats where enzootic circulation occurs [4,7,8]. Because human
VEE is nearly impossible to distinguish clinically from other
tropical viral diseases such as dengue, most cases are probably
undiagnosed. Endemic VEE is therefore grossly underreported in
many parts of the Americas where enzootic circulation occurs and
surveillance for febrile illness is limited.
To further characterize human disease caused by enzootic
VEEV, we studied 42 cases of VEEV infection characterized by
virus isolation, some accompanied by neurological disease,
detected in Panama from 1961–2004. Here we describe the
clinical signs and symptoms of disease, ecological conditions
accompanying VEEV exposure and genetic characterizations of
the etiologic VEEV strains.
Methods
Virus isolates
VEEV isolates from infected persons, included in the study, are
shown in Table 1. The retrospective analyses of these isolates and
reporting of clinical data were approved by the Institutional
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University of Texas Medical Branch. Most of the viruses were
isolated in Vero cells or by intracerebral inoculation of newborn
mouse brains with sera from febrile patients, with triturated
mosquito pools, or with rodent tissues (approved by the
institutional animal care and use committees of the Gorgas
Memorial Institute and the University of Texas Medical Branch).
Supernatant fluids from infected cells or brain homogenates were
stored at 270uC and later used for the extraction of viral RNA.
Plaque assays
To determine the viremia levels in infected patients, available
sera were tested by plaque assay as previously described [9] using
Vero cells.
Viral RNA extraction and cDNA synthesis
RNA was extracted from virus stocks as described previously
[10]. A 250 ml volume of the 10% homogenized mouse brain
tissue or supernatant was mixed with 750 ml of Trizol LS (Gibco-
BRL, Gaithersburg, MD) and RNA was extracted following the
manufacturer’s protocol. Synthesis of cDNA was performed by
mixing 5 ml of the RNA (1/10
th of the extracted RNA) with
1 mmol of reverse primer V9207B(2), 16 First Strand Buffer
(Gibco), 1 mM dNTPs, 80 U RNAsin (Promega, Madison, WI)
and 200 U SuperScript II Reverse Transcriptase (Gibco). The
reaction was incubated at 42uC for 1 h.
PCR amplification, sequencing and phylogenetic analysis
PCR was carried out using primers V8369(+) (GAGAACTGC-
GAGCAATGGTCA) and V9207B(2) (TRCACTGGCT-
GAACTGTT) as previously described [8]. These primers amplify
the N-terminus of the PE2 envelope glycoprotein precursor gene, a
region that has been used extensively in VEEV phylogenetic
analyses [8,11,12] and is known to undergo critical amino acid
substitutions associated with epidemic VEEV emergence [10].
The 816 bp PCR product was sequenced directly using primers
V8659 (AATTGAGGCAGTGAAGAGCGAC) and V8953B
(CTGCCTACAGGATTAAAT) using an Applied Biosystems
(Foster City, CA) Prism automated DNA sequencing kit following
the manufacturer’s protocol. Sequences were aligned using
MacVector program (Oxford Molecular Group, Campbell, CA)
and phylogenetic analyses were performed using the maximum
parsimony and neighbor joining programs implemented in the
PAUP 4.0 software [13] or with MrBayes 3.0 [14] with 1,000,000
iterations. Bootstrap analyses were conducted using neighbor
joining with 1,000 replicates to place confidence values on
grouping within the trees [15].
Results
Distribution of the VEEV cases in Panama
Data from recent VEE cases we studied (1990–2004) were
compared with those from the literature dating to 1961. Recent
VEE cases in Panama were reported in the provinces of Darien,
Panama, Cocle, Veraguas and Bocas del Toro (Figure 1). Two
clusters of cases were observed - one covering the Darien province
and the second covering Panama Province (central Panama).
Darien, the largest and most sparsely populated of the regions,
extends from the hinterlands of Panama Province to the
Colombian border, comprising more than one-third of the
national territory. The land in Darien is characterized by forest
and swamps and thus includes large areas of habitat for the Culex
(Melanoconion) vectors of enzootic VEEV and small rodents that
serve as the principal reservoir host [16]. The second cluster of
cases was observed in Panama Province, between Gatun and
Bayano Lakes. The surrounding area is characterized by rainforest
and swamps habitats and is also conducive to enzootic VEEV
circulation [6,17,18,19]. Cases of VEE in Panama were reported
in patients whose age ranged from 10 months to 48 years old. The
more severe cases with neurological complications were observed
in children.
Description of the VEE cases
The VEE cases we studied, as well as those previously reported
and included here for comparative purposes, were characterized
by fever, headache, tremors, nausea, vomiting and diarrhea
(Table 1). Only 3 of the cases developed neurological complica-
tions, and 2 of these were fatal. All cases of neurological disease
were children less than 15 years of age. Overall, the most common
signs and symptoms among the 33 VEE patients for which data
were available included fever (94%), headache (55%), retroorbital
pain (27%) and tremors (27%)(Table 2). These common signs and
symptoms would not distinguish VEE from a wide variety of other
tropical diseases, including malaria and dengue, without labora-
tory diagnostics. The overall case fatality rate of the Panamanian
cases with known outcomes was 2/39, or 5% (Table 1). This rate is
higher than that reported during most VEE epidemics (typically
less than 1%) [20], which could reflect greater recognition of
milder cases when more active surveillance is being conducted
during outbreaks.
Viremia titers
To investigate whether humans infected with subtype ID
enzootic VEEV develop viremia titers sufficient to infect potential
mosquito vectors, we quantified the virus titers in the sera of 5
patients (the only ones from which virus was isolated that were still
available) using plaque assay. Titers varied from 3.0610
2 to
6.7610
5 PFU/ml (Table 3). Because the sera may not have been
sampled at the time of peak viremia, these titers may underesti-
mate maximum viremia levels.
Phylogenetic analyses
To investigate genetic relationships among the VEEV strains
from Panama in comparison to others isolated from different
regions of the Americas, phylogenetic analyses were performed.
Maximum parsimony, neighbor joining and Bayesian methods all
generated similar tree topologies. The neighbor-joining tree based
on the partial PE2 sequences (Figure 2) showed that most of the
Author Summary
Venezuelan equine encephalitis (VEE) is a mosquito-borne
viral disease that has caused major epidemics in many
parts of Latin America and has even spread into Texas on
one occasion. These epidemics result from spillover to
humans of a horse-mosquito-horse amplification cycle that
has occurred periodically since the 1920s. However,
between these equine-mediated epidemics, little attempt
is typically made to detect VEE in humans. Here, we show
that VEE virus strains that typically circulate in a mosquito-
rodent cycle, termed enzootic strains, also produce many
cases of severe and sometimes fatal disease in Panama in
the absence of apparent epidemics. These endemic
infections are probably rarely detected because they are
difficult to distinguish clinically from dengue fever, another
mosquito-borne viral illness common in the tropics. Our
findings underscore endemic VEE as an important but
usually neglected arboviral disease of Latin America.
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Strain
GenBank Acc.
No.* Location (Province, site)
Year of
isolation Host
Age
(Years)** Passage history
Signs and
symptoms***
4840 FJ969477 Panama 1961 Human unknown BHK-1, SMB-2,V-1, CEC-1 unknown
BT-2607 AF004450 Bocas del Toro, Almirante 1961 Mosquito NA ?, BHK-1 NA
3880 L00930* Panama, Can ˜ito 1961 Human 14 SMB-2, V-2 1, 2, 4, 5, 10, 19***
8137 U88634* El Rinco ´n 1962 Human unknown SMB-1, V-1 unknown
8138 FJ969478 El Rinco ´n 1962 Human unknown CEC-2 unknown
8585 FJ969479 El Rinco ´n 1962 Human unknown Unknown unknown
202330 U88635* Panama, Gamboa 1963 Rodent NA SMB-1, V-2 NA
P. Quintero U88636* Panama, Juan Mina 1964 Human unknown CEC-1, V-1 unknown
F-322 U88638* Panama, Can ˜ito 1965 N.K. unknown Unknown unknown
240832 U88637* Panama, Gamboa 1965 N.K. unknown CEC-1, V-1 unknown
MARU23283 FJ969485 Panama, Bayano 1977 Human unknown Unknown unknown
GML903104 U88639* Panama, Bayano 1977 Mosquito NA Unknown NA
MARU29136 FJ969469 Panama, Alto de Jobo 1981 Human unknown Unknown unknown
GML903837 FJ969476 Panama, Bayano 1984 Mosquito unknown Unknown unknown
GML903843 U88640* Panama, Bayano 1984 Mosquito unknown V-1, BHK-1 unknown
487317 FJ969467 Veraguas Santiago 1990 Human 47 V-3 1, 2
489243 FJ969474 Panama, San Miguelito Chilibre 1991 Human .1 5 V - 4 1 ,2 ,3 ,4 ,5 ,6 ,7 ,8
93P1513 U88641* Panama, Lake Gatun 1993 Human 27 SMB-1, V-1 unknown
489245 FJ969472 Panama, Felipillo 1995 Human 21 V-4 1, 2, 3
489246 FJ969470 Cocle, Aguadulce 1995 Human 24 V-4 1, 2, 9
489247 FJ969471 Panama, Felipillo 1996 Human .15 V-4 1, 9, 10
474590 FJ969449 Panama, Mananitas 1997 Human 16 V-2 1, 2, 3, 9, 11, 12, 16
487315 FJ969463 Panama, Felipillo 1997 Human 28 V-3 1, 2, 3, 4, 5, 6, 9, 10, 11, 13
487308 FJ969457 Darien, Sambu 1998 Human 10 V-2 1, 2, 3, 4, 11
487309 FJ969458 Darien, Sambu 1998 Human 16 V-2 1, 2, 9, 11
487310 FJ969459 Darien, Sambu 1998 Human 15 V-3 1, 2, 9, 11, 13
487311 FJ969460 Darien, Sambu 1998 Human 9 V-3 1, 2, 11
487312 FJ969461 Darien, Sambu 1998 Human 23 V-3 1, 2, 4, 10
487313 FJ969462 Darien, Sambu 1998 Human 39 V-3 1, 9, 10, 11
487314 FJ969466 Darien, Sambu 1998 Human 18 V-3 1, 2, 10
481460 FJ969450 Panama, Felipillo 2000 Human 16 V-2 1
484551 FJ969451 Darien, R Iglesias 2001 Human 15 V-2 1
484918 FJ969452 Darien, Yaviza 2001 Human 5 V-2 1
485028 FJ969453 Darien, Yaviza 2001 Human 9 V-2 1
485029 FJ969454 Darien, Yaviza 2001 Human 9 V-2 1
485030 FJ969455 Darien, Yaviza 2001 Human 3 V-2 1
489242 FJ969475 Darien, R Iglesias 2001 Human 10 V-3 1
487321 FJ969465 Darien, Yaviza 2001 Human 5 V-3 1, 5, 15, 19
486729 FJ969456 Darien, Meteti 2002 Human 20 V-1 1, 2, 3, 4, 5, 6
212857 FJ969484 Darien, Santa Fe 2003 Human 10 SMB-1 1, 2, 3, 5, 14
212863 FJ969480 Darien, Santa Fe 2003 Human 2 SMB-1 1, 5
212908 FJ969482 Darien, Santa Fe 2003 Human 15 SMB-1 1, 2, 4, 11, 14, 17
213391 FJ969483 Bocas del Toro, Guabito 2003 Human 13 SMB-1 16, 18
213413 FJ969481 Panama, Pacora 2003 Human 26 SMB-1 1, 2, 3, 10, 11
490021 FJ998042 Panama, El Cacao 2004 Human 12 unknown 16
490006 FJ998043 Panama, La Trinidad 2004 Human 12 unknown 1
489607 FJ998044 Colon, Escobal 2004 Human 48 unknown 1
*Sequence determined previously.
**NA=not applicable.
***1=Fever; 2=headache, 3=tremors; 4=nausea; 5=vomiting; 6=diarrhea; 7=rash; 8=renal/hepatic failure; 9=arthralgia; 10=myalgia; 11=retroorbital pain;
12=exanthema; 13=sore throat; 14=back pain; 15=convulsion; 16=encephalitis; 17=cough; 18=hemorrhage; 19=fatal.
***Data previously reported by Johnson et al. [6].
doi:10.1371/journal.pntd.0000472.t001
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with previously sequenced Panamanian subtype ID strains as well
as some Peruvian ID isolates. This group was previously called the
Panama-Peru subtype ID genotype [21]. Within this group, 2
distinct clades among the Panamanian strains were observed: 1)
strains from Central Panama; 2) isolates from Eastern Panama
(Darien). The final subtype ID isolate, strain 213391 from western
Panama (Bocas del Toro Province), was phylogenetically distinct
from all other ID isolates. Our phylogenies placed it outside of the
Panama/Peru genotype, but this placement was supported by a
bootstrap value of only 69%. The location of collection of this
strain was geographically close to those of subtype IE strains
isolated in the 1960s (Fig. 2). Therefore, the geographic ranges of
subtypes ID and IE may overlap slightly.
Figure 1. Map of Panama showing the locations of the Venezuelan equine encephalitis cases.
doi:10.1371/journal.pntd.0000472.g001
Table 2. Clinical signs and symptoms in 33 cases of
Venezuelan equine encephalitis evaluated in Panama from
1961–2004.
Sign/symptom % of patients exhibiting
Fever 94
Headache 55
Retroorbital pain 27
Tremors 27
Nausea 21
Vomiting 21
Arthralgia 21
Myalgia 21
Diarrhea 9
Encephalitis 9
Sore throat 6
Back pain 6
Rash 3
Renal/hepatic failure 3
Exanthema 3
Convulsions 3
Cough 3
Hemorrhage 3
Fatality 6
doi:10.1371/journal.pntd.0000472.t002
Table 3. Viremia titers in febrile patients infected with VEEV.
Code Serum titer (PFU/ml)
213413 2610
2
213388 ,10
2
212857 7610
3
212908 1.2610
3
212860 ,10
2
213391 6.7610
5
212863 2.0610
4
doi:10.1371/journal.pntd.0000472.t003
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In 1961, the first evidence of VEEV in Panama was obtained
when the virus was isolated from a fatal human case. The patient,
a 14-year-old boy, resided in Can ˜ito, near Gatun lake [6]. Since
then, febrile disease associated with VEEV has been reported in
the vicinity of Gatun and Bayano Lakes and in the province of
Darien, all areas of rainforest and swamp habitat. Our results
indicate that VEEV infection in at least 2 regions of Panama may
be common, and the clinical features of the disease evaluated in 33
acute individuals suggest that only laboratory diagnostics can
distinguish VEE from other febrile, tropical diseases such as
malaria, dengue and Mayaro fever that present with overlapping
signs and symptoms. Thus, the incidence of VEE in Panama and
other endemic regions of Latin America is probably grossly
underreported because malaria and dengue are assumed to be the
etiologies of all febrile illnesses in the absence of laboratory
diagnostics. Because exposure to VEEV involves vectors with
different temporal and spatial distributions than those of dengue
and malaria [20,22], improved VEE diagnosis could lead to better
prevention methods to reduce human exposure.
For subtype ID VEEV, the highest viremia titers that we
measured in infected persons are presumably capable of orally
infecting and being transmitted by several mosquito species
including the proven subtype IE enzootic VEEV vector Cx.
(Mel.) taeniopus [23], and the proven and potential epidemic VEEV
vectors Psorophora confinnis [24], Ae. taeniorhynchus [25,26], Ae.
albopictus [27] and Ae. aegypti [28]. Although infection thresholds
have not been determined for natural, enzootic subtype ID
vectors, we believe that it is likely that they could be infected by
feeding on persons with titers on the order that we measured.
Furthermore, serum titers and mosquito transmission potential
could be even higher if the individuals we studied were not
sampled at the peak of viremia. Previous studies have reported that
horses infected with epidemic VEEV strains develop comparable
viremia levels, which allow them to serve as highly efficient
amplifying hosts by infecting susceptible mosquitoes [29,30,31].
These results suggest the possibility that humans infected with
subtype ID VEEV in Panama could support an epidemic human-
mosquito-human transmission cycle, especially if a viremic
individual reached an urban area with abundant Ae. aegypti or
Ae. albopictus. These species, especially the former, are highly
efficient vectors of other human arboviruses such as dengue [32]
and chikungunya [33] due to their ecology and behavior as well as
their susceptibility to infection. Interestingly, VEE is endemic in
Iquitos, Peru, where Ae. aegypti is abundant and transmits DENV to
thousands of people during epidemics. However, the average
number of diagnosed VEE human cases per year in Peru is about
ten, but this is probably a gross underestimate of the true number
(P.V. Aguilar, unpublished). Because VEEV viremia in humans is
Figure 2. Phylogenetic tree generated from partial PE2 gene sequences of Panamanian VEEV strains and homologous VEE complex
alphavirus sequences from the GenBank library. The tree was produced using the neighbor joining program implemented in PAUP 4.0 [13].
VEEV strains are denoted by abbreviated country and year of isolation, followed by strain designation. Panamanian strains include abbreviated
province in parentheses as follows: BT – Bocas del Toro; COC – Cocle; COL – Colon; DA – Darien; PA – Panama; VE – Veraguas. Numbers indicate
bootstrap values for clades.
doi:10.1371/journal.pntd.0000472.g002
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Iquitos might be expected. However, only one VEE human
outbreak has been reported in Iquitos (in 2006) [8] despite
detection of endemic VEE there since 1993 [12]. Thus, additional
factors not yet understood may be crucial to the emergence of
enzootic VEE. Mutations that arise during the adaptation of the
virus to certain mosquito species have been previously described as
a key factor in the epizootic VEE emergence, and thus deserve
further study [1,34]. Other factors such as mosquito abundance
should also be investigated.
Hemorrhagic manifestations among VEE cases are rare. To
date, only two patients (,15 years of age) have been reported with
hemorrhagic complications upon VEEV infection with the
subtype ID Panama/Peru genotype [35]. Interestingly, one of
the VEE patients from Panama that we studied also reported
hemorrhagic manifestations and encephalitis, although the former
was not determined to be the cause of death. Thus, although
hemorrhages associated with VEEV infection are unusual, they do
occur and their potential role in a fatal outcome should be
investigated.
One of the Panamanian patients infected with VEEV from
1990–2004 developed a fatal encephalitic disease, further
confirming that subtype ID Panama/Peru genotype can cause
fatal disease. Although subtype ID Panama/Peru lineage strains
have been continuously associated with human illness in Peru,
fatal disease has never been reported there despite many cases in
children [8]. The reasons for this lack of fatal VEE in Peru remain
unknown, but could include underreporting in many locations
where laboratory diagnosis is not readily available.
Our phylogenetic analyses revealed that all Panamanian isolates
with one exception belong to the previously described Panama/
Peru genotype [21,36]. Within this group, 2 distinct clades among
the Panamanian strains were observed: one sampled from Central
Panama, and a second from Eastern Panama (Darien). A third
Panamanian ID lineage was identified in western Panama (Bocas
del Toro), which may represent a new, major lineage in subtype
ID. Longer sequences may be needed to definitively determine the
relationship of this new lineage to the other ID genotypes.
Interestingly, this Bocas del Toro isolate was recovered from a
patient who presented with encephalitis and hemorrhagic
complications. Thus, further studies are needed to investigate
whether this specific genotype is particularly associated with severe
encephalitis and hemorrhagic disease. In addition, future genetic
analyses of the Panamanian and Peruvian isolates associated with
hemorrhagic disease could provide important insights about the
viral determinants (if any) of this infrequent disease manifestation.
Potential host factors/conditions should also be investigated for
their role in disease outcome.
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